Related Experiment Video

Updated: Jun 29, 2025

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.1K

A Novel Inhibitor of Poly(ADP-Ribose) Polymerase-1 Inhibits Proliferation of a BRCA-Deficient Breast Cancer Cell Line

Yonglong Jin1,2, Lijie Wang1, Chengxue Jin3,4

  • 1Department of Radiotherapy, The Affiliated Hospital of Qingdao University, Qingdao 266000, China.

Chemical Research in Toxicology
|March 27, 2024
PubMed

Insights

A new drug, 4F-DDC, selectively targets BRCA-mutant breast cancer cells by inducing DNA damage and activating the cGAS-STING pathway. This PARP inhibitor shows significant potential for treating BRCA-deficient tumors through synthetic lethality.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Loss-of-function mutations in BRCA1/2 are common in breast cancer.
  • PARP inhibitors exploit synthetic lethality in BRCA-deficient cells.
  • A novel PARP1 inhibitor, 4F-DDC, was previously synthesized with potent activity.

Purpose of the Study:

  • To investigate the antitumor mechanisms of 4F-DDC in vitro and in vivo.
  • To explore the selective efficacy of 4F-DDC against BRCA-mutant cancer cells.
  • To elucidate the molecular pathways activated by 4F-DDC.

Main Methods:

  • In vitro proliferation assays using BRCA-mutant cell lines (HCC-1937).
  • Apoptosis and cell cycle analysis (G2/M arrest).
  • Immunofluorescence and Western blot for DNA damage and cGAS-STING pathway activation.
  • In vivo tumor xenograft studies.

Main Results:

  • 4F-DDC selectively inhibited proliferation of BRCA-mutant cells, particularly HCC-1937.
  • 4F-DDC induced apoptosis and G2/M cell cycle arrest in HCC-1937 cells.
  • 4F-DDC triggered DNA double-strand breaks and activated the cGAS-STING pathway.
  • 4F-DDC suppressed tumor growth in vivo via DNA damage and cGAS-STING activation.

Conclusions:

  • 4F-DDC exhibits potent antitumor activity against BRCA-mutant breast cancer.
  • The mechanism involves DNA damage induction and cGAS-STING pathway activation.
  • 4F-DDC demonstrates significant therapeutic potential for BRCA-deficient breast cancers.

More Related Videos

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

28.6K
Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

4.0K

Related Concept Videos

DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.4K
Restarting Stalled Replication Forks02:37

Restarting Stalled Replication Forks

DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
5.8K